Current Report Filing (8-k)
March 26 2014 - 8:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 26, 2014
Mast Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-32157 |
|
84-1318182 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
12390 El Camino Real, Suite 150, San Diego,
California |
|
92130 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: 858-552-0866
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On March 26, 2014, Mast Therapeutics, Inc. issued a press release announcing its financial results for the three months and year ended December 31,
2013. A copy of the press release is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is
incorporated by reference to the Exhibit Index filed with this report.
The information set forth under Item 2.02 and in Exhibit 99.1 is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language
in any such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Mast Therapeutics, Inc. |
|
|
|
|
March 26, 2014 |
|
|
|
By: |
|
/s/ Patrick L. Keran |
|
|
|
|
|
|
Name: Patrick L. Keran |
|
|
|
|
|
|
Title: President and Chief Operating Officer |
Exhibit Index
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release dated March 26, 2014 |
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Apr 2023 to Apr 2024